Skip to content

A multicentre randomized controlled study on improving Sarcopenia in elderly patients with Baduanjin

A multicentre randomized controlled study on improving Sarcopenia in elderly patients with Baduanjin

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000887
Enrollment
Unknown
Registered
2024-12-28
Start date
2025-02-01
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcopenia

Interventions

control group:Health education + dietary guidance
treatment group:Baduanjin training + health education + diet guidance

Sponsors

Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 80 Years

Inclusion criteria

Inclusion criteria: The diagnostic criteria for possible sarcopenia were calf circumference (male < 34cm female < 33cm) SARC-F scale =4 points and grip strength (male < 28kg female < 18kg). Inclusion criteria (1) Meet the above diagnostic criteria; (2) 65= age =80; (3) Gender is not limited; (4) Can complete daily activities and basic communication independently without mental and neurological disorders and can correctly understand the scale; (5) I or the person living with me can use smart devices such as smart phones; (6) Voluntarily participate in this study and sign the informed consent.

Exclusion criteria

Exclusion criteria: Exclusion criteria (1) Contraindications for sports rehabilitation (Appendix 2); (2) Refer to the Chinese Medical Association "Guidelines for the Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease" patients with severity of ?-? COPD patients; (3) Patients with serious diseases of liver and kidney; (4) Patients with malignant tumors who are undergoing chemotherapy radiation therapy or have developed bone metastases; (5) Sprain fracture serious joint deformation and other mobility difficulties balance function decline resulting in unable to complete the exercise treatment program; (6) Severe fractures with a T-value =-2.5SD and one or more fragility fractures.

Design outcomes

Primary

MeasureTime frame
30 seconds sitting and standing test;Hand grip strength test;

Secondary

MeasureTime frame
Balance function test;Simple physical fitness scale;The six-minute walk test;Body composition test;Security Index;Soft tissue tension;Muscle electrophysiological test;Quality of life assessment;Musculoskeletal ultrasound;Exercise habit scale;

Countries

China

Contacts

Public ContactXiao Jing

Xiyuan Hospital of China Academy of Chinese Medical Sciences

58280244@sina.com15601233308

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026